Serial litigator Vanda Pharmaceuticals appears to have exhausted all options in its legal battle against Hetlioz (tasimelteon) abbreviated new drug application sponsors Teva and Apotex, after the US Supreme Court denied the originator’s petition for a writ of certiorari review of a decisive patent-litigation loss for its landmark sleep disorder drug.
While Vanda was “disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law,” it was “pleased that our case has drawn attention to an area of law